Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a comprehensive business update. CEO Commentary: “Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned